Diabetes Care:良好的血糖和血压控制有益于延长糖尿病患者生存期

2013-04-29 Diabetes Care 丁香园

  为了比较2型糖尿病(T2DM)长期存活者和死亡者的临床特征。来自印度马德拉斯糖尿病研究基金会的Mohan博士等人进行了一项研究,研究发现,T2DM长期存活者有较好的血糖和血压控制以及脂类代谢。研究结果在线发表于2013年4月5日的美国《糖尿病护理》(Diabetes Care)杂志上。   研究人员对200,000多名患者的医疗记录进行回顾性调查后,确定T2DM存活者(糖尿病病程>40

  为了比较2型糖尿病(T2DM)长期存活者和死亡者的临床特征。来自印度马德拉斯糖尿病研究基金会的Mohan博士等人进行了一项研究,研究发现,T2DM长期存活者有较好的血糖和血压控制以及脂类代谢。研究结果在线发表于2013年4月5日的美国《糖尿病护理》(Diabetes Care)杂志上。

  研究人员对200,000多名患者的医疗记录进行回顾性调查后,确定T2DM存活者(糖尿病病程>40年)和与其发病年龄及性别匹配的T2DM死亡者。对并发症发病率和死亡原因进行分析。采用视网膜摄影术诊断视网膜病。对两组患者微量白蛋白尿和大量白蛋白尿、外周血管疾病(踝臂指数<0.9)、冠状动脉疾病(有心肌梗塞或冠状动脉重建术病史)、神经病变(振动知觉阈值>20V)进行比较。

  结果显示,糖尿病存活者(n=238)平均病程43.7±3.9年,死亡患者(n=307)死亡时病程22.4±11.0年(P<0.001)。与长期存活者比较,死亡患者收缩压和舒张压、血糖、HbA1c、血清胆固醇、LDL胆固醇和甘油三酯显著升高,HDL胆固醇显著降低(除收缩压P=0.027外,其它指标P<0.001)。最常见的死亡原因为心肌梗塞(46.4%)和肾衰竭(16.6)。由于病程长和年龄较大,存活者的并发症发病率比死亡患者高,二者比较如下:视网膜病:76%vs.62%;微量白蛋白尿:39.1%vs.27.3%;大量白蛋白尿,8.4%vs.23.7%;神经病变:86.5%vs.63.5%;外周血管疾病:23.1%vs.11.4%;冠状动脉疾病:44.5%vs.40.7%。

  研究表明,T2DM长期存活患者有较好的血糖和血压控制,以及更有利的脂类代谢。

糖尿病相关的拓展阅读:


Clinical Profile of Long-Term Survivors and Nonsurvivors With Type 2 Diabetes.
OBJECTIVE
To compare clinical profile of long-term survivors and nonsurvivors with type 2 diabetes (T2DM).
RESEARCH DESIGN AND METHODS
After conducting a retrospective survey of >200,000 case records, we identified T2DM survivors (>40 years of duration) and age at diagnosis and sex-matched T2DM nonsurvivors. Prevalence of complications and causes of death were analyzed. Retinopathy was diagnosed by retinal photography. Microalbuminuria and macroalbuminuria, peripheral vascular disease based on ankle-brachial index <0.9, coronary artery disease, based on history of myocardial infarction or coronary revascularization, and neuropathy, based on vibration perception threshold >20 V, were compared in both groups.
RESULTS
The mean duration of diabetes of survivors (n = 238) was 43.7 ± 3.9 years and that of the nonsurvivors (n = 307), at time of death, was 22.4 ± 11.0 years (P < 0.001). Nonsurvivors had significantly higher systolic and diastolic blood pressures, plasma glucose, HbA1c, serum cholesterol, LDL cholesterol, triglycerides, and lower HDL cholesterol compared with long-term survivors (P < 0.001 for all parameters except systolic blood pressure, which was P = 0.027). Myocardial infarction (46.4%) and renal failure (16.6%) were the most common causes of death. Prevalence of most complications were higher among survivors because of longer duration and older age, as follows, for survivors versus nonsurvivors: retinopathy, 76 vs. 62%; microalbuminuria, 39.1 vs. 27.3%; macroalbuminuria, 8.4 vs. 23.7%; neuropathy, 86.5 vs. 63.5%; peripheral vascular disease, 23.1 vs. 11.4%; and coronary artery disease, 44.5 vs. 40.7%.
CONCLUSIONS
Long-term survivors with T2DM had better glycemic and blood pressure control and more favorable lipid profiles.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759270, encodeId=e0da1e59270b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Nov 27 20:57:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901076, encodeId=fb9919010e675, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Jul 18 01:57:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636655, encodeId=4c9a16366557c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Mar 25 06:57:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932465, encodeId=130819324657b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 20 13:57:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5686, encodeId=a3d256867a, content=希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc1580659, createdName=XiaoSHuang1126, createdTime=Sat May 04 14:36:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378024, encodeId=dc1d13e8024c1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446266, encodeId=26b81446266cb, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473698, encodeId=ef6414e369862, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759270, encodeId=e0da1e59270b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Nov 27 20:57:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901076, encodeId=fb9919010e675, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Jul 18 01:57:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636655, encodeId=4c9a16366557c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Mar 25 06:57:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932465, encodeId=130819324657b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 20 13:57:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5686, encodeId=a3d256867a, content=希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc1580659, createdName=XiaoSHuang1126, createdTime=Sat May 04 14:36:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378024, encodeId=dc1d13e8024c1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446266, encodeId=26b81446266cb, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473698, encodeId=ef6414e369862, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759270, encodeId=e0da1e59270b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Nov 27 20:57:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901076, encodeId=fb9919010e675, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Jul 18 01:57:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636655, encodeId=4c9a16366557c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Mar 25 06:57:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932465, encodeId=130819324657b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 20 13:57:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5686, encodeId=a3d256867a, content=希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc1580659, createdName=XiaoSHuang1126, createdTime=Sat May 04 14:36:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378024, encodeId=dc1d13e8024c1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446266, encodeId=26b81446266cb, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473698, encodeId=ef6414e369862, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759270, encodeId=e0da1e59270b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Nov 27 20:57:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901076, encodeId=fb9919010e675, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Jul 18 01:57:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636655, encodeId=4c9a16366557c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Mar 25 06:57:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932465, encodeId=130819324657b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 20 13:57:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5686, encodeId=a3d256867a, content=希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc1580659, createdName=XiaoSHuang1126, createdTime=Sat May 04 14:36:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378024, encodeId=dc1d13e8024c1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446266, encodeId=26b81446266cb, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473698, encodeId=ef6414e369862, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759270, encodeId=e0da1e59270b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Nov 27 20:57:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901076, encodeId=fb9919010e675, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Jul 18 01:57:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636655, encodeId=4c9a16366557c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Mar 25 06:57:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932465, encodeId=130819324657b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 20 13:57:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5686, encodeId=a3d256867a, content=希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc1580659, createdName=XiaoSHuang1126, createdTime=Sat May 04 14:36:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378024, encodeId=dc1d13e8024c1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446266, encodeId=26b81446266cb, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473698, encodeId=ef6414e369862, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
    2013-05-04 XiaoSHuang1126

    希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1759270, encodeId=e0da1e59270b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Nov 27 20:57:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901076, encodeId=fb9919010e675, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Jul 18 01:57:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636655, encodeId=4c9a16366557c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Mar 25 06:57:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932465, encodeId=130819324657b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 20 13:57:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5686, encodeId=a3d256867a, content=希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc1580659, createdName=XiaoSHuang1126, createdTime=Sat May 04 14:36:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378024, encodeId=dc1d13e8024c1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446266, encodeId=26b81446266cb, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473698, encodeId=ef6414e369862, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1759270, encodeId=e0da1e59270b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Nov 27 20:57:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901076, encodeId=fb9919010e675, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Jul 18 01:57:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636655, encodeId=4c9a16366557c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Mar 25 06:57:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932465, encodeId=130819324657b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 20 13:57:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5686, encodeId=a3d256867a, content=希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc1580659, createdName=XiaoSHuang1126, createdTime=Sat May 04 14:36:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378024, encodeId=dc1d13e8024c1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446266, encodeId=26b81446266cb, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473698, encodeId=ef6414e369862, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1759270, encodeId=e0da1e59270b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Nov 27 20:57:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901076, encodeId=fb9919010e675, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Jul 18 01:57:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636655, encodeId=4c9a16366557c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Mar 25 06:57:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932465, encodeId=130819324657b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Dec 20 13:57:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5686, encodeId=a3d256867a, content=希望作者能继续深入研究 让糖尿病患者能早日找到合适的药物 早日康复, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc1580659, createdName=XiaoSHuang1126, createdTime=Sat May 04 14:36:00 CST 2013, time=2013-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378024, encodeId=dc1d13e8024c1, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446266, encodeId=26b81446266cb, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473698, encodeId=ef6414e369862, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Tue Apr 30 23:57:00 CST 2013, time=2013-04-30, status=1, ipAttribution=)]

相关资讯

Diabetes Care:糖尿病增高骨折相关住院风险

  2012年12月17日在线发表于《糖尿病护理》(Diabetes Care )的一项研究显示,被确诊为糖尿病的成年人,其骨折相关住院风险明显升高。   该研究由美国马里兰州巴尔的摩市约翰斯·霍普金斯大学Bloomberg公共卫生学院流行病学系的Andrea L.C. Schneider极其同事完成,是一项基于社区的大型研究。研究者表示,这一结果支持美国糖尿病学会在合适的患者人群中评估骨折风险

Diabetes Care:间歇性低氧可降低血糖

  在糖尿病低氧可能导致自主神经功能失调。间歇性低氧(IH),一种改善低氧适应的技术,在2型糖尿病患者可以改善心肺反射,并且最终改善血糖浓度。为了验证一个回合的间歇性低氧是否能够发起一个可能导致更好低氧适应的持久反应,来自奥地利因斯布鲁克大学医学部的Luciano Bernardi教授及其团队进行了一项研究,该研究发现一个回合的间歇性低氧诱导一个初步的低氧适应,伴随心肺反射的改善和血糖的

Diabetes Care:耐力锻炼可更持续降低血糖

     加拿大学者的一项研究表明,与有氧锻炼相比,耐力锻炼期间血糖初始降低程度较小,但运动后血糖降低持续时间较长。论文于2012年11月19日在线发表于《糖尿病护理》(Diabetes Care)杂志。   此项研究共纳入12例平素进行体能活动的1型糖尿病患者。受试者进行45分钟耐力锻炼、45分钟有氧锻炼或在间隔期不进行锻炼。在锻炼期间和之后60分钟测定血糖。利用持续血糖监测在锻炼

J Clin Endocrinol Metab:肾移植患者不用强化血糖控制

  美国新泽西州的Hermayer KL博士今日发表在《临床内分泌杂志》上的研究表明:不建议肾移植患者术后进行强化血糖控制治疗。   研究人员对接受肾移植的患者进行了一项随机对照试验,将104例患者随机分配到强化组或对照组,强化组接受静脉胰岛素治疗IV(强化)治疗,对照组接受标准皮下胰岛素注射SC治疗。强化组肾移植后3天接受强化IV胰岛素治疗【血糖(BG)为70~110mg/dl】,对

Diabetes Care:lixisenatide有效改善二甲双胍控制不佳的2型糖尿病人群的血糖

为了评价利西拉来(lixisenatide,每日1次20μg,早餐和晚餐前给药)辅助治疗二甲双胍控制不佳的2型糖尿病患者的有效性和安全性,来自瑞典隆德大学的Ahrén博士等人进行了一项研究,研究发现,利西拉来可显著改善二甲双胍控制不佳的2型糖尿病患者的血糖控制,且药物耐受性良好。研究结果在线发表于2013年3月27日美国的《糖尿病护理》(Diabetes Care)杂志上。研究人员对680名二甲双

JGIM:血糖达标非糖尿病患者心血管获益关键

  一项纳入2.6万余例受试者的观察性研究显示,对于2型糖尿病患者,收缩压(SBP,<130 mm Hg)或低密度脂蛋白胆固醇(LDL-C,<100 mg/dl)达标与心血管疾病(CVD)住院风险的降低显著相关,而糖化血红蛋白(HbA1c)达标(<7%)并不是CVD住院风险降低的独立因素。(J Gen Intern Me